Last reviewed · How we verify
NCT03856281: IMPRESS II
Intermittent Pneumatic Compression for Treating Lower Limb Lymphoedema
NA trial testing Intermittent Pneumatic Compression in Lymphoedema of Leg in 50 participants. Completed in 10 December 2019.
10 December 2019
Quick facts
| Lead sponsor | Cwm Taf University Health Board (NHS) |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 10 July 2018 |
| Primary completion | 10 December 2019 |
| Estimated completion | 10 December 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Intermittent Pneumatic Compression
Conditions studied
- Lymphoedema of Leg — all drugs for Lymphoedema of Leg →
Sponsor
Cwm Taf University Health Board (NHS)
Who can join
Adults 18 to 85, any sex, with Lymphoedema of Leg. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The treatment of lymphoedema and its associated complications represent a considerable drain on increasingly limited NHS resources. Intermittent pneumatic compression (IPC) represents an innovative treatment for this condition, however the efficacy of IPC as a treatment for lower limb lymphoedema needs to be investigated via robust clinical research.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03856281
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intermittent Pneumatic Compression
Trials testing the same drug.
- NCT07197996 — The RETRAIN Trial Phase 2 · NA · recruiting
- NCT03806322 — A Better Way to Decrease Knee Swelling in Patients With Knee Osteoarthritis · NA · completed
Other Cwm Taf University Health Board (NHS) trials
Trials by the same sponsor.
- NCT05968209 — The Impact of Probiotic Supplementation on General Well Being · NA · completed
- NCT05645081 — Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke · recruiting
- NCT05171998 — Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes · completed
- NCT04729452 — Characterisation of the Immune Response to SARS-CoV-2 / COVID-19 · completed
- NCT05391035 — The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03856281 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cwm Taf University Health Board (NHS)
- Last refreshed: 27 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03856281.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing